Literature DB >> 11179522

Influence of gender on early and one-year clinical outcomes after saphenous vein graft stenting.

J M Ahmed1, G Dangas, A J Lansky, R Mehran, M K Hong, G S Mintz, A D Pichard, L F Satler, K M Kent, G W Stone, M B Leon.   

Abstract

Compared with men, women may have a worse prognosis after native coronary revascularization. However, the influence of gender on clinical outcomes after saphenous vein graft (SVG) stenting is unknown. The purpose of this study was to compare early and 1-year clinical outcomes between men and women after stent implantation in SVG. A total of 1,199 consecutive patients with 1,858 SVG lesions were studied. Procedural success, in-hospital events, and late clinical outcomes were compared between men (n = 951) and women (n = 248). Overall procedural success was similar between men and women (97% vs 96%, p = NS). However, in-hospital (3.2% vs 1.6%, p = 0.07) and 30-day cumulative (4.4% vs 1.9%, p = 0.02) mortality rates were higher in women than in men. In addition, women had a higher incidence of vascular complications (12% vs 7.3%, p = 0.006) and postprocedural acute renal failure (8.1% vs 4%, p = 0.02). At 1-year follow-up, mortality was 13% in women and 11% in men (p = NS) and target lesion revascularization was 18% versus 23%, respectively (p = NS). By multivariate regression analysis, independent correlates of in-hospital mortality were female gender (odds ratio [OR] 3.6, confidence interval [CI] 1.0 to 12.5, p = 0.05) and left ventricular ejection fraction (OR 0.9, CI 0.9 to 1.0, p = 0.01). Female gender was found to predict 30-day mortality (OR 2.5, CI 1.1 to 5.5, p = 0.02). The sole predictor of 1-year mortality was diabetes mellitus (OR 1.6, CI 1.1 to 2.3, p = 0.01). This study shows that women compared with men treated with stent implantation in SVG lesions have (1) a trend toward higher in-hospital mortality, (2) higher risk of 30-day mortality, (3) increased incidence of vascular complications and postprocedure acute renal failure, and (4) similar 1-year clinical outcome.

Entities:  

Mesh:

Year:  2001        PMID: 11179522     DOI: 10.1016/s0002-9149(00)01391-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Current State of the Art in Approaches to Saphenous Vein Graft Interventions.

Authors:  Michael Lee; Jeremy Kong
Journal:  Interv Cardiol       Date:  2017-09

2.  Procedural Results and Immediate Outcomes following De Novo Saphenous Venous Graft Interventions.

Authors:  Lalita Nemani; Maddury Jyotsna; Malleswara Rao D
Journal:  Int J Angiol       Date:  2018-03-26

Review 3.  Coronary revascularisation in women.

Authors:  G W Mikhail
Journal:  Heart       Date:  2006-05       Impact factor: 5.994

Review 4.  Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization.

Authors:  Frans J Beerkens; Bimmer E Claessen; Marielle Mahan; Mario F L Gaudino; Derrick Y Tam; José P S Henriques; Roxana Mehran; George D Dangas
Journal:  Nat Rev Cardiol       Date:  2021-10-05       Impact factor: 32.419

5.  Long-term outcomes of percutaneous coronary interventions within coronary artery bypass grafts.

Authors:  Rafał Januszek; Zbigniew Siudak; Artur Dziewierz; Tomasz Rakowski; Dariusz Dudek; Stanisław Bartuś
Journal:  Arch Med Sci       Date:  2019-01-30       Impact factor: 3.318

6.  Long-Term Clinical Outcomes of Percutaneous Coronary Intervention in Saphenous Vein Grafts in a Low to Middle-Income Country.

Authors:  Ghufran Adnan; Intisar Ahmed; Javed Tai; Maria Ali Khan; Hammad Hasan
Journal:  Cureus       Date:  2020-11-16

7.  Coronary aspirate TNFα reflects saphenous vein bypass graft restenosis risk in diabetic patients.

Authors:  Theodor Baars; Thomas Konorza; Philipp Kahlert; Stefan Möhlenkamp; Raimund Erbel; Gerd Heusch; Petra Kleinbongard
Journal:  Cardiovasc Diabetol       Date:  2013-01-10       Impact factor: 9.951

Review 8.  Advances in the Post-coronary Artery Bypass Graft Management of Occlusive Coronary Artery Disease.

Authors:  Mohammed Shamim Rahman; Ruben de Winter; Alex Nap; Paul Knaapen
Journal:  Interv Cardiol       Date:  2021-12-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.